The Silicon Review
At Myriad, our goal is to make a difference in patients’ lives and our work has been guided by this mission throughout the Company’s history.
Myriad is focused on revolutionizing patient care through the discovery, development, and marketing of transformative molecular diagnostic tests that address pressing clinical needs across multiple medical specialties.
Since 1991, Myriad has invested heavily in educating patients and healthcare professionals about the role genes and proteins play in disease. Millions of patients have already benefited from Myriad’s tests, which helps healthcare professionals better manage and tailor medical care.
Today, Myriad continues this strong tradition. It is expanding its reach and increasing its impact on patient care by introducing new molecular diagnostic and companion diagnostic tests for a growing number of diseases.
The firm is also focused on expanding internationally in an effort to broaden its geographic footprint and provide its life-saving products and services to patients and healthcare professionals around the world.
From its birthplace in Salt Lake City, Utah, Myriad has expanded its resources and its reach to include a global community:Myriad is present in 128 countries: 16 in which it has direct subsidiaries and 112 in which it has 44 distributors on 6 continents.
The company values
As Myriadians, we are…
Passionate About Patients worldwide and transforming their lives with the
Pioneering Spirit to lead a revolution in healthcare through breakthrough discoveries, acting as
Trusted Advisors to patients and physicians earned by a relentless pursuit of perfection and professional integrity as part of a
United Team born out of the utmost respect for each other and a singular outward focus on patient care.
More than 25 years as a Leader in Molecular Diagnostics
Myriad Genetics was founded in 1991, 10 years before the human genome was sequenced, making Myriad one of the first genomics companies in history. Today, Myriad is the pioneer and leader in molecular diagnostics, offering innovative products that transform patients’ lives. These products include leading molecular diagnostic tests for hereditary cancer, urological cancer, autoimmune disorders, depression, and other diseases. The firm is excited about the future and remain committed to advancing the science of personalized medicine as itsdevelop more products to address unmet medical needs.
Myriad’s molecular diagnostic products are designed to assess an individual’s risk for developing disease so that action can be taken to prevent or delay its onset.
The company’s prognostic medicine products assess a patient’s risk of disease progression and recurrence so that a healthcare professional knows how aggressively to treat the disease. Its companion diagnostic products identify a patient’s likelihood of responding to a particular therapy to ensure optimal treatment decisions.
The need to save lives and improve the quality of life for patients is a global imperative that knows no boundaries.Myriad is dedicated to providing patients and healthcare professionals around the world with accurate, clinically valuable information that improves, enhances and individualizes patient care. As part of this commitment, Myriad has established its International Headquarters in Zurich, Switzerland, a full-service laboratory in Munich, Germany and sales offices in Munich; Paris, France; Madrid, Spain; Milan, Italy, and Zurich.
Myriad also works with a global network of distributors to bring its transformative molecular diagnostic tests to patients who need them.
The leading man
Mark C. Capone, President, and CEO:
Mark C. Capone is president and CEO of Myriad Genetics. He previously served as president of Myriad Genetic Laboratories from March 2010 to June 2015. Mr. Capone joined the company in October 2002. Prior to joining Myriad, he served 17 years with Eli Lilly and Company where he held positions as product development manager, manufacturing plant manager, and area sales director. Mr. Capone received his B.S. degree in Chemical Engineering from Penn State University graduating with the highest distinction and his M.S. degree in Chemical Engineering from Massachusetts Institute of Technology. He also earned a Master of Science in Management from the Sloan School of Management at the Massachusetts Institute of Technology. In 2012, Mr. Capone was elected Outstanding Engineering Alumnus at Penn State and is a member of the Industrial and Professional Advisory Council along with Advisory Board for the Hershey Medical Center for Innovation, both at Penn State. He currently serves on the Board of the American Clinical Laboratory Association and is a Member of the Board of Trustees for Pioneer Theatre Company in Salt Lake City.